Swedish-based Smartcella has entered an agreement with a research team from the Karolinska Institute for the exclusive rights to advance a cell replacement therapy for Parkinson’s disease into clinical development and commercialization. The Karolinska Institute team in Sweden, led by Johan Ericson, PhD, a professor of developmental biology, has…
Researchers at Virginia Commonwealth University have developed prototypes of wearable devices that use pressure sensors and vibrations to address freezing of gait, a hallmark symptom of Parkinson’s disease. One such device is a specialized shoe sole equipped with sensors. These sensors detect changes in pressure as the wearer takes…
Kenai Therapeutics is setting up research and laboratory facilities at Lilly Gateway Labs in San Diego, to help advance RNDP-001, its investigational dopaminergic neuron replacement therapy for Parkinson’s disease. By joining Gateway Labs, Kenai, formerly Ryne Biotechnologies, will have access to state-of-the-art facilities, along with resources and…
Newronika plans to use the 13.6 million euros (about $14.3 million) raised in a funding round to support what could be a pivotal clinical trial of its adaptive deep brain stimulation (DBS) system, designed to adjust treatment in real time to better control the symptoms of Parkinson’s disease…
Wearable sensors that monitor motor symptoms like tremor can accurately assess eligibility of Parkinson’s disease patients for apomorphine pump therapy, aligning closely with traditional clinical evaluations, according to a study. The findings suggest that wearable sensors have “the potential to revolutionize the way patients are assessed and treated, ultimately…
A research initiative aims to create a mobile app using artificial intelligence (AI) to make strength training at home more effective for people with Parkinson’s disease and other neurological conditions. The technology is being developed by Myworkout AS, in collaboration with the Norwegian University of Science and Technology…
Supernus Pharmaceuticals is on track to make Onapgo (apomorphine hydrochloride) — its newly approved medication for treating motor fluctuations in advanced Parkinson’s disease — available to patients in the U.S. by summer. That’s according to Jonathan Rubin, MD, chief medical officer at Supernus, who said that, by…
People with chronic kidney disease, a condition characterized by a progressive loss of kidney function, have alpha-synuclein protein deposits in their kidneys, a study in China has found. Alpha-synuclein is a key marker of Parkinson’s disease, suggesting a possible link between kidney function and the neurodegenerative condition. “These findings are…
People with tremor-dominant Parkinson’s disease experience a higher burden of nonmotor symptoms than people with essential tremor (ET), according to a recent report. Overall nonmotor symptom severity, urinary symptoms, and loss of smell are among the factors that most clearly diverged between the two conditions. Researchers believe the…
Levels of the protein epidermal growth factor, or EGF, in blood may help predict the risk of cognitive decline in people with Parkinson’s disease, a study reports. The study, “Correlation between plasma epidermal growth factor and follow-up cognitive decline in Parkinson’s disease,” was published in Neurological…
Get regular updates to your inbox.
